Attorney Morgan Tilleman was quoted in a Health Leaders article, “CMS Tries to Shore Up ACA with Proposed Rule. It May Be Too Late,” on August 31, 2016. The article discussed the Centers for Medicare & Medicaid Services proposed changes to the Affordable Care Act and to its method of risk adjustment in an attempt to satisfy the insurance companies struggling with the success of Obamacare. Tilleman explained how concerns over the survivability of the exchanges and concerns from insurers are likely motivating CMS. He was quoted saying, “This year, large risk-adjustment payments have been blamed for exacerbating the financial struggles of some co-ops. Also, a number of lawsuits have been brought against HHS and CMS alleging that the risk adjustment formula is unfair to some issuers. While CMS was likely going to change some of the features of the risk adjustment formula and process regardless, the controversy swirling around risk adjustment may have impacted CMS’s timeline and focused attention on this issue.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”